Killing drug-resistant melanoma requires combination therapy

Researchers report that melanoma that have become resistant to PLX4032 and other BRAF inhibitors will signal around the blocked proteins by shifting rerouting signaling pathways. They also show how to overcome this resistance by simultaneously targeting two additional proteins. The researchers see this as further evidence that some cancers must be treated with multiple targeted drugs at the outset of treatment.

Read the whole article on Science Daily

More from Science Daily